Alterations in gene expression profiles during prostate cancer progression: functional correlations to tumorigenicity and down-regulation of selenoprotein-P in mouse and human tumors.

To identify molecular changes that occur during prostate tumor progression, we have characterized a series of prostate cancer cell lines isolated at different stages of tumorigenesis from C3(1)/Tag transgenic mice. Cell lines derived from low- and high-grade prostatic intraepithelial neoplasia, invasive carcinoma, and a lung metastasis exhibited significant differences in cell growth, tumorigenicity, invasiveness, and angiogenesis. cDNA microarray analysis of 8700 features revealed correlations between the tumorigenicity of the C3(1)/Tag-Pr cells and changes in the expression levels of genes regulating cell growth, angiogenesis, and invasion. Many changes observed in transcriptional regulation in this in vitro system are similar to those reported for human prostate cancer, as well as other types of human tumors. This analysis of expression patterns has also identified novel genes that may be involved in mechanisms of prostate oncogenesis or serve as potential biomarkers or therapeutic targets for prostate cancer. Examples include the L1-cell adhesion molecule, metastasis-associated gene (MTA-2), Rab-25, tumor-associated signal transducer-2 (Trop-2), and Selenoprotein-P, a gene that binds selenium and prevents oxidative stress. Many genes identified in the Pr-cell line model have been shown to be altered in human prostate cancer. The comprehensive microarray data provides a rational basis for using this model system for studies where alterations of specific genes or pathways are of particular interest. Quantitative real-time reverse transcription-PCR for Selenoprotein-P demonstrated a similar down-regulation of the transcript of this gene in a subset of human prostate tumors, mouse tumors, and prostate carcinoma cell lines. This work demonstrates that expression profiling in animal models may lead to the identification of novel genes involved in human prostate cancer biology.

[1]  J. Köllermann,et al.  Expression of vascular endothelial growth factor (VEGF) and VEGF receptor Flk-1 in benign, premalignant, and malignant prostate tissue. , 2001, American journal of clinical pathology.

[2]  T. H. van der Kwast,et al.  Modulation of cytokeratin subtype, EGF receptor, and androgen receptor expression during progression of prostate cancer. , 1998, Human pathology.

[3]  Bruce W. Turnbull,et al.  Effects of Selenium Supplementation for Cancer Prevention in Patients With Carcinoma of the Skin: A Randomized Controlled Trial , 1996 .

[4]  C. Wild,et al.  A critical evaluation of the application of biomarkers in epidemiological studies on diet and health , 2001, British Journal of Nutrition.

[5]  J. Green,et al.  Prostate and mammary adenocarcinoma in transgenic mice carrying a rat C3(1) simian virus 40 large tumor antigen fusion gene. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[6]  F. Hamdy,et al.  Localization and quantification of mRNA for matrix metalloproteinase‐2 (MMP‐2) and tissue inhibitor of matrix metalloproteinase‐2 (TIMP‐2) in human benign and malignant prostatic tissue , 1997, The Prostate.

[7]  O. Cussenot,et al.  htert expression correlates with MYC over‐expression in human prostate cancer , 2000, International journal of cancer.

[8]  Y. Surh,et al.  Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. , 2001, Mutation research.

[9]  T. Stamey,et al.  Growth responses of normal, benign hyperplastic, and malignant human prostatic epithelial cells in vitro to cholera toxin, pituitary extract, and hydrocortisone , 1986, The Prostate.

[10]  M. Shen,et al.  Molecular genetics of prostate cancer. , 2000, Genes & development.

[11]  M. Shibata,et al.  Development and characterization of a mouse prostate adenocarcinoma cell line: Ductal formation determined by extracellular matrix , 1998, The Prostate.

[12]  Taylor Murray,et al.  Cancer Statistics, 2001 , 2001, CA: a cancer journal for clinicians.

[13]  J. Arthur,et al.  Selenium, selenoproteins and human health: a review , 2001, Public Health Nutrition.

[14]  T. Flam,et al.  Epidemiology of Prostatic Cancer , 1990, The Journal of international medical research.

[15]  K. Mita,et al.  Expression of the insulin‐like growth factor system and cancer progression in hormone‐treated prostate cancer patients , 2000, International journal of urology : official journal of the Japanese Urological Association.

[16]  Richard Simon,et al.  Initiating oncogenic event determines gene-expression patterns of human breast cancer models , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[17]  J. Morrow,et al.  Pathogenesis of diquat‐induced liver necrosis in selenium‐deficient rats: Assessment of the roles of lipid peroxidation and selenoprotein P , 1995, Hepatology.

[18]  W. Isaacs,et al.  The cadherin cell-cell adhesion pathway in prostate cancer progression. , 1997, British journal of urology.

[19]  H. Klocker,et al.  Regulation of prostatic growth and function by peptide growth factors , 1996, The Prostate.

[20]  O. Kallioniemi,et al.  ANX7, a candidate tumor suppressor gene for prostate cancer , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[21]  S. Clark,et al.  Loss of annexin II heavy and light chains in prostate cancer and its precursors. , 2001, Cancer research.

[22]  Schr,et al.  Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. , 1994, The American journal of pathology.

[23]  R. Hurst,et al.  Loss of tissue transglutaminase as a biomarker for prostate adenocarcinoma , 2000, Cancer.

[24]  G. MacLennan,et al.  Chemoprevention of prostate carcinogenesis by α-difluoromethylornithine in TRAMP mice , 2000 .

[25]  A. Montgomery,et al.  Involvement of integrin alpha(v)beta(3) and cell adhesion molecule L1 in transendothelial migration of melanoma cells. , 2001, Molecular biology of the cell.

[26]  M. Arenas,et al.  E-, N- And P-cadherin, and α-, β- and γ-catenin Protein Expression in Normal, Hyperplastic and Carcinomatous Human Prostate , 2000, The Histochemical Journal.

[27]  K. Griffiths,et al.  Vascular endothelial growth factor (VEGF) expression in prostatic tumours and its relationship to neuroendocrine cells. , 1996, British Journal of Cancer.

[28]  Jeffrey E. Green,et al.  Development of PIN and prostate adenocarcinoma cell lines: a model system for multistage tumor progression. , 2002, Neoplasia.

[29]  M. Webber,et al.  Human cell lines as an in vitro/in vivo model for prostate carcinogenesis and progression , 2001, The Prostate.

[30]  S. Garrett,et al.  Metallothionein isoform 1 and 2 gene expression in the human prostate: Downregulation of MT‐1X in advanced prostate cancer , 2000, The Prostate.

[31]  K. Matsusue,et al.  Characterization of mouse metastasis-associated gene 2: genomic structure, nuclear localization signal, and alternative potentials as transcriptional activator and repressor. , 2001, DNA and cell biology.

[32]  C. Wood,et al.  Tumor-suppressive activity of CD66a in prostate cancer , 1999, Cancer Gene Therapy.

[33]  W. Almers,et al.  Annexin 2 has an essential role in actin-based macropinocytic rocketing , 2001, Current Biology.

[34]  N. Scollan,et al.  In vivo measurement of lipogenesis in ruminants using [1-(14)C]acetate. , 2001, The British journal of nutrition.

[35]  R. Burk,et al.  Liver necrosis and lipid peroxidation in the rat as the result of paraquat and diquat administration. Effect of selenium deficiency. , 1980, The Journal of clinical investigation.

[36]  A. Tsang,et al.  Expression and characterization of a dictyostelium discoideum annexin , 1994, Molecular and Cellular Biochemistry.

[37]  A. Scorilas,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 2001 by The Endocrine Society Insulin-Like Growth Factor I (IGF-I) and IGF-Binding Protein-3 in Benign Prostatic Hyperplasia and Prostate Cancer , 2022 .

[38]  G. Haas,et al.  The frequency of carcinoma and intraepithelial neoplasia of the prostate in young male patients. , 1993, The Journal of urology.

[39]  J. Cheville,et al.  The cell cycle inhibitors p21WAF1 and p27KIP1 are associated with survival in patients treated by salvage prostatectomy after radiation therapy. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  J. Green,et al.  2-difluoromethylornithine and dehydroepiandrosterone inhibit mammary tumor progression but not mammary or prostate tumor initiation in C3(1)/SV40 T/t-antigen transgenic mice. , 2001, Cancer research.

[41]  B W Turnbull,et al.  Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. A randomized controlled trial. Nutritional Prevention of Cancer Study Group. , 1996, JAMA.

[42]  C. Sheehan,et al.  Co-downregulation of cell adhesion proteins alpha- and beta-catenins, p120CTN, E-cadherin, and CD44 in prostatic adenocarcinomas. , 2001, Human pathology.

[43]  C. Cordon-Cardo,et al.  Overexpression of cyclin D1 is associated with metastatic prostate cancer to bone. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  J. Ward,et al.  Progression of prostatic intraepithelial neoplasia to invasive carcinoma in C3(1)/SV40 large T antigen transgenic mice: histopathological and molecular biological alterations. , 1996, Cancer research.

[45]  E. Constant,et al.  Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. , 1998 .